Navigating 4 Analyst Ratings For Elevance Health
Portfolio Pulse from Benzinga Insights
Elevance Health (NYSE:ELV) has received mixed analyst ratings over the past three months, with 4 somewhat bullish ratings. The average 12-month price target is $555.00, with a high of $574.00 and a low of $547.00, reflecting a 2.72% decrease from the previous average. Analysts from RBC Capital, Cantor Fitzgerald, and JP Morgan have provided updates, with actions ranging from maintaining to raising and lowering ratings and price targets. Elevance Health is a major health insurer in the U.S. with significant market capitalization, revenue growth, and financial performance indicators such as net margin, ROE, and ROA, but carries a higher debt-to-equity ratio.
January 25, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Elevance Health has received somewhat bullish ratings from analysts, with a slight decrease in the average price target. The company's strong financial performance and market position may continue to attract investor interest despite the mixed ratings.
The somewhat bullish ratings and the slight decrease in the average price target suggest a neutral short-term impact on ELV's stock price. The company's solid financial metrics and market position may mitigate any negative effects from the ratings. However, the higher debt-to-equity ratio could be a concern for some investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100